The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
(1) Background: Sodium–glucose co-transporter 2 inhibitors (SGLT2is) increase uric acid excretion. The intensity of uricosuria is linked to glycosuria. (2) Methods: We aim to analyze the effect of SGLT2 inhibitors on urinary fractional excretion (FE) of uric acid and glucose in patients with type 2...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/5/1360 |
| _version_ | 1797264295043530752 |
|---|---|
| author | Paula Sánchez-Briales María Marques Vidas Paula López-Sánchez María Victoria López-Illázquez Lucía Martín-Testillano Aylin Vedat-Ali Jose Portolés |
| author_facet | Paula Sánchez-Briales María Marques Vidas Paula López-Sánchez María Victoria López-Illázquez Lucía Martín-Testillano Aylin Vedat-Ali Jose Portolés |
| author_sort | Paula Sánchez-Briales |
| collection | DOAJ |
| description | (1) Background: Sodium–glucose co-transporter 2 inhibitors (SGLT2is) increase uric acid excretion. The intensity of uricosuria is linked to glycosuria. (2) Methods: We aim to analyze the effect of SGLT2 inhibitors on urinary fractional excretion (FE) of uric acid and glucose in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in a single-center retrospective study with patients with T2DM and CKD who started on treatment with SGLT2is. Patients on renal replacement therapy or with glucagon-like peptide-1 (GLP1) analogs were excluded. Subgroup analysis was performed according to the estimated glomerular filtration rate (eGFR), the SGLT2i molecule, the main comorbidities, and concomitant treatment. As a secondary objective, the study analyzed the effect of SGLT2 inhibitors on uricemia levels. (3) Results: Seventy-three patients were analyzed, with a mean follow-up of 1.2 years. Uric acid and glucose FE significantly increased after the initiation of SGLT2is. This increase remained stable during the follow-up without differences among eGFR groups. No significant reduction in uricemia was observed. However, a trend towards a decrease was observed. (4) Conclusion: The use of SGLT2is in patients with CKD and T2DM is associated with an increase in uric acid FE, which maintains stability irrespective of glomerular filtration loss at least during 24 months of follow-up. |
| first_indexed | 2024-04-25T00:26:37Z |
| format | Article |
| id | doaj.art-6b5b607e16ad4455b9fe4d0513211dba |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-04-25T00:26:37Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-6b5b607e16ad4455b9fe4d0513211dba2024-03-12T16:48:10ZengMDPI AGJournal of Clinical Medicine2077-03832024-02-01135136010.3390/jcm13051360The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes MellitusPaula Sánchez-Briales0María Marques Vidas1Paula López-Sánchez2María Victoria López-Illázquez3Lucía Martín-Testillano4Aylin Vedat-Ali5Jose Portolés6Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, SpainNephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, SpainNephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, SpainNephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, SpainNephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, SpainNephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, SpainNephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana (IDIPHISA), 28222 Madrid, Spain(1) Background: Sodium–glucose co-transporter 2 inhibitors (SGLT2is) increase uric acid excretion. The intensity of uricosuria is linked to glycosuria. (2) Methods: We aim to analyze the effect of SGLT2 inhibitors on urinary fractional excretion (FE) of uric acid and glucose in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in a single-center retrospective study with patients with T2DM and CKD who started on treatment with SGLT2is. Patients on renal replacement therapy or with glucagon-like peptide-1 (GLP1) analogs were excluded. Subgroup analysis was performed according to the estimated glomerular filtration rate (eGFR), the SGLT2i molecule, the main comorbidities, and concomitant treatment. As a secondary objective, the study analyzed the effect of SGLT2 inhibitors on uricemia levels. (3) Results: Seventy-three patients were analyzed, with a mean follow-up of 1.2 years. Uric acid and glucose FE significantly increased after the initiation of SGLT2is. This increase remained stable during the follow-up without differences among eGFR groups. No significant reduction in uricemia was observed. However, a trend towards a decrease was observed. (4) Conclusion: The use of SGLT2is in patients with CKD and T2DM is associated with an increase in uric acid FE, which maintains stability irrespective of glomerular filtration loss at least during 24 months of follow-up.https://www.mdpi.com/2077-0383/13/5/1360chronic kidney diseasefractional excretionSGLT2 inhibitorstype 2 diabetes mellitusuric acid |
| spellingShingle | Paula Sánchez-Briales María Marques Vidas Paula López-Sánchez María Victoria López-Illázquez Lucía Martín-Testillano Aylin Vedat-Ali Jose Portolés The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus Journal of Clinical Medicine chronic kidney disease fractional excretion SGLT2 inhibitors type 2 diabetes mellitus uric acid |
| title | The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus |
| title_full | The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus |
| title_fullStr | The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus |
| title_full_unstemmed | The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus |
| title_short | The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus |
| title_sort | uricosuric effect of sglt2 inhibitors is maintained in the long term in patients with chronic kidney disease and type 2 diabetes mellitus |
| topic | chronic kidney disease fractional excretion SGLT2 inhibitors type 2 diabetes mellitus uric acid |
| url | https://www.mdpi.com/2077-0383/13/5/1360 |
| work_keys_str_mv | AT paulasanchezbriales theuricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT mariamarquesvidas theuricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT paulalopezsanchez theuricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT mariavictorialopezillazquez theuricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT luciamartintestillano theuricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT aylinvedatali theuricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT joseportoles theuricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT paulasanchezbriales uricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT mariamarquesvidas uricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT paulalopezsanchez uricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT mariavictorialopezillazquez uricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT luciamartintestillano uricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT aylinvedatali uricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus AT joseportoles uricosuriceffectofsglt2inhibitorsismaintainedinthelongterminpatientswithchronickidneydiseaseandtype2diabetesmellitus |